Northwest Biotherapeutics (NWBO) Capital Expenditures (2010 - 2026)

Northwest Biotherapeutics' Capital Expenditures history runs 16 years deep, the most recent figure standing at $129000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 38.71% year-over-year to $129000.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 77.42% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 48.32% from the prior year.
• Capital Expenditures fell to $129000.0 in Q1 2026 per NWBO's latest filing, from $905000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $2.2 million in Q4 2022 and bottomed at $58000.0 in Q1 2022.
• The 5-year median for Capital Expenditures is $304000.0 (2025), against an average of $528588.2.
• Across the five-year window, Capital Expenditures slumped 89.74% in 2022 and jumped 2198.28% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at $2.2 million in 2022, then slumped by 80.65% to $418000.0 in 2023, then plunged by 81.34% to $78000.0 in 2024, then surged by 1060.26% to $905000.0 in 2025, then sank by 85.75% to $129000.0 in 2026.
• Per Business Quant, the three latest NWBO Capital Expenditures figures stand at $129000.0 (Q1 2026), $905000.0 (Q4 2025), and $202000.0 (Q3 2025).